{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:06Z","timestamp":1787032806841,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,20]]},"DOI":"10.7759\/cureus.43794","type":"journal-article","created":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T09:26:45Z","timestamp":1692523605000},"source":"Crossref","is-referenced-by-count":2,"title":["A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience"],"prefix":"10.7759","author":[{"given":"Laura","family":"Jimbu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Valeanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trifa","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Bojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Parvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana C","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Torok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Urian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Vasilache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","unstructured":"Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973, 57:485-8.","journal-title":"Cancer Chemother Rep"},{"key":"ref2","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai KR","year":"1981","unstructured":"Rai KR, Holland JF, Glidewell OJ, et al.. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981, 58:1203-1212.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al.. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021, 11:41. 10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106318","article-title":"IImproved post remission survival of non- favorable risk acute myelogenous leukemia (AML) patients following initial remission induction therapy with flag+\/-idarubicin versus 3 + 7 (anthracycline + cytarabine)","volume":"93","author":"Solh MM","year":"2020","unstructured":"Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. IImproved post remission survival of non- favorable risk acute myelogenous leukemia (AML) patients following initial remission induction therapy with flag+\/-idarubicin versus 3 + 7 (anthracycline + cytarabine). Leuk Res. 2020, 93:106318. 10.1016\/j.leukres.2020.106318","journal-title":"Leuk Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1239","article-title":"Outcome of acute myeloid leukaemia in Nigeria: clinician's perspective","volume":"15","author":"Ogbenna AA","year":"2021","unstructured":"Ogbenna AA, Oyedeji OA, Famuyiwa CO, et al.. Outcome of acute myeloid leukaemia in Nigeria: clinician's perspective. Ecancermedicalscience. 2021, 15:1239. 10.3332\/ecancer.2021.1239","journal-title":"Ecancermedicalscience"},{"key":"ref7","article-title":"Treatment outcome of acute myeloid leukemia in Egypt: a developing country perspective","volume":"1","author":"Zawam H","year":"2018","unstructured":"Zawam H, salama r, Alsirafy SA, Bishr MK. Treatment outcome of acute myeloid leukemia in Egypt: a developing country perspective. Int J Cancer Treatment. 2018, 1:53-59.","journal-title":"Int J Cancer Treatment"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1917002","article-title":"The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry","volume":"60","author":"Semerad L","year":"2021","unstructured":"Semerad L, Sustkova Z, Cetkovsky P, et al.. The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry. Acta Oncol. 2021, 60:818-23. 10.1080\/0284186X.2021.1917002","journal-title":"Acta Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.02.002","article-title":"Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American Center","volume":"18","author":"Jaime-P\u00e9rez JC","year":"2018","unstructured":"Jaime-P\u00e9rez JC, Padilla-Medina JR, Fern\u00e1ndez LT, Herrera-Garza JL, Guti\u00e9rrez-Aguirre CH, Tar\u00edn-Arzaga L, G\u00f3mez-Almaguer D. Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American Center. Clin Lymphoma Myeloma Leuk. 2018, 18:286-92. 10.1016\/j.clml.2018.02.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch D","year":"2013","unstructured":"Averbuch D, Orasch C, Cordonnier C, et al.. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013, 98:1826-35. 10.3324\/haematol.2013.091025","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089417","article-title":"Effects of \u03b2-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea","volume":"9","author":"Knecht H","year":"2014","unstructured":"Knecht H, Neulinger SC, Heinsen FA, et al.. Effects of \u03b2-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One. 2014, 9:e89417. 10.1371\/journal.pone.0089417","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006805","article-title":"Wicked: the untold story of ciprofloxacin","volume":"14","author":"Conley ZC","year":"2018","unstructured":"Conley ZC, Bodine TJ, Chou A, Zechiedrich L. Wicked: the untold story of ciprofloxacin. PLoS Pathog. 2018, 14:e1006805. 10.1371\/journal.ppat.1006805","journal-title":"PLoS Pathog"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.02.003","article-title":"Early mortality in acute myeloid leukemia","volume":"39","author":"Hahn A","year":"2015","unstructured":"Hahn A, Giri S, Yaghmour G, Martin MG. Early mortality in acute myeloid leukemia. Leuk Res. 2015, 39:505-9. 10.1016\/j.leukres.2015.02.003","journal-title":"Leuk Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29319","article-title":"Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis","volume":"121","author":"Percival ME","year":"2015","unstructured":"Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015, 121:2004-12. 10.1002\/cncr.29319","journal-title":"Cancer"},{"key":"ref15","article-title":"The factors affecting early death after the initial therapy of acute myeloid leukemia","volume":"8","author":"Malkan UY","year":"2015","unstructured":"Malkan UY, Gunes G, Eliacik E, et al.. The factors affecting early death after the initial therapy of acute myeloid leukemia. Int J Clin Exp Med. 2015, 8:22564-9.","journal-title":"Int J Clin Exp Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler B","year":"2006","unstructured":"Deschler B, L\u00fcbbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006, 107:2099-107. 10.1002\/cncr.22233","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00553","article-title":"Acute myeloid leukemia in Qatar (2010-2016): clinical, biological, and prognostic factors and treatment outcomes","volume":"11","author":"El Omri H","year":"2020","unstructured":"El Omri H, Taha RY, Elomri A, et al.. Acute myeloid leukemia in Qatar (2010-2016): clinical, biological, and prognostic factors and treatment outcomes. Front Genet. 2020, 11:553. 10.3389\/fgene.2020.00553","journal-title":"Front Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13035","article-title":"Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis","volume":"15","author":"Helles\u00f8y M","year":"2021","unstructured":"Helles\u00f8y M, Engen C, Grob T, L\u00f6wenberg B, Valk PJ, Gjertsen BT. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Mol Oncol. 2021, 15:2285-99. 10.1002\/1878-0261.13035","journal-title":"Mol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17523","article-title":"Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia","volume":"194","author":"Wiernik PH","year":"2021","unstructured":"Wiernik PH, Sun Z, Cripe LD, et al.. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021, 194:309-18. 10.1111\/bjh.17523","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2018.1492925","article-title":"Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)","volume":"7","author":"Acharya UH","year":"2018","unstructured":"Acharya UH, Halpern AB, Wu QV, et al.. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018, 7:51-3. 10.1080\/21556660.2018.1492925","journal-title":"J Drug Assess"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum FR","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, et al.. Age and acute myeloid leukemia. Blood. 2006, 107:3481-5. 10.1182\/blood-2005-09-3724","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2740","article-title":"The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia","volume":"9","author":"Liu CJ","year":"2020","unstructured":"Liu CJ, Hong YC, Kuan AS, et al.. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. Cancer Med. 2020, 9:1572-80. 10.1002\/cam4.2740","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14631","article-title":"Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia","volume":"177","author":"Ho G","year":"2017","unstructured":"Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan TH. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. Br J Haematol. 2017, 177:791-9. 10.1111\/bjh.14631","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki K","year":"2022","unstructured":"Sasaki K, Kadia T, Begna K, et al.. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022, 97:68-78. 10.1002\/ajh.26395","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser M","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, et al.. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020, 31:697-712. 10.1016\/j.annonc.2020.02.018","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040592","article-title":"Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD","volume":"96","author":"de Jonge HJ","year":"2011","unstructured":"de Jonge HJ, Valk PJ, de Bont ES, Schuringa JJ, Ossenkoppele G, Vellenga E, Huls G. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011, 96:1310-7. 10.3324\/haematol.2011.040592","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600572673","article-title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","volume":"47","author":"Greenwood MJ","year":"2006","unstructured":"Greenwood MJ, Seftel MD, Richardson C, et al.. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006, 47:1245-52. 10.1080\/10428190600572673","journal-title":"Leuk Lymphoma"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-133377","article-title":"Prognostic value of initial blood cell counts in acute myeloid leukemia","volume":"136","author":"Kirby E","year":"2020","unstructured":"Kirby E, Markert R, Marinella M. Prognostic value of initial blood cell counts in acute myeloid leukemia. Blood. 2020, 136:1-10.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson G","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, et al.. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009, 113:4179-87. 10.1182\/blood-2008-07-172007","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600627055","article-title":"De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center","volume":"47","author":"Fagundes EM","year":"2006","unstructured":"Fagundes EM, Rocha V, Gl\u00f3ria AB, et al.. De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006, 47:1557-64. 10.1080\/10428190600627055","journal-title":"Leuk Lymphoma"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170009-a-survival-analysis-of-acute-myeloid-leukemia-patients-treated-with-intensive-chemotherapy-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:03:02Z","timestamp":1707490982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170009-a-survival-analysis-of-acute-myeloid-leukemia-patients-treated-with-intensive-chemotherapy-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.43794","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,20]]}}}